Eman Y. Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eman Y. Ahmed has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Hanem Mohamed Awad
Tanning Materials and Leather Technology Department, National Research Centre, Dokki, Cairo, 12622, Egypt
5 shared publications - Omaima Mohamed Abdelhafez
Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki, Cairo, Egypt
5 shared publications Aya M. Serry
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt
4 shared publicationsMai M. Elghonemy
Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt
4 shared publications- Nehad Ahmed Abdel Latif
Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt
4 shared publications Rasha Z. Batran
4 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (37) , 39987-39998
Design, synthesis, anticancer activity and molecular modeling of new pyrazoline derivatives as telomerase inhibitors
Telomerase is an enzyme that rebuilds chromosomal ends called telomeres, allowing cells to keep dividing.
- 12 August 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (37) , 39987-39998
Open AccessDesign, synthesis, anticancer activity and molecular modeling of new pyrazoline derivatives as telomerase inhibitors
Telomerase is an enzyme that rebuilds chromosomal ends called telomeres, allowing cells to keep dividing.
- Open Access
- 21 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Exploring the impact of the innovative compound 3-(3-(4-hydroxy-2-oxo-2H-chromen-3-yl)-5-(pyridin-3-yl)-1H-pyrazol-1-yl) indolin-2-one on accelerating wound recovery
Wound healing represents a significant challenge within the field of medical science. Contemporary clinical practices increasingly favor the utilization of herbal compounds to facilitate the repair process. Among these compounds, coumarin-a phytochemical noted for its antibacterial and wound-healing properties-has garnered considerable attention. This study investigates the potential advantages of incorporating coumarin into wound dressings within an experimental model. Our synthesized target compound 3-(3-(4-hydroxy-2-oxo-2 H -chromen-3-yl)-5-(pyridin-3-yl)-1 H -pyrazol-1-yl) indolin-2-one ( CPPI ) demonstrated notable antimicrobial activity against the pathogenic Staphylococcus aureus MRSA, Bacillus cereus , and Pseudomonas aeruginosa . Moreover, both in vitro and in vivo experiments showed that CPPI significantly enhanced the migration of skin fibroblast cells and promoted the wound healing process. Furthermore, it facilitated complete re-epithelialization of the wounds. Histological analysis revealed the formation of well-structured granulation tissue and a reduction in indicators of wound infection, evidenced by a minimal presence of inflammatory cells in comparison to untreated wounds. Additionally, in silico molecular docking studies of CPPI indicated significant binding affinity within COX-2 active site along with a stable complex during molecular dynamics simulations. Collectively, the findings of this study suggest that CPPI can provide a protective effect against infections in cutaneous wounds, attributable to its antimicrobial properties.
- 21 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessExploring the impact of the innovative compound 3-(3-(4-hydroxy-2-oxo-2H-chromen-3-yl)-5-(pyridin-3-yl)-1H-pyrazol-1-yl) indolin-2-one on accelerating wound recovery
Wound healing represents a significant challenge within the field of medical science. Contemporary clinical practices increasingly favor the utilization of herbal compounds to facilitate the repair process. Among these compounds, coumarin-a phytochemical noted for its antibacterial and wound-healing properties-has garnered considerable attention. This study investigates the potential advantages of incorporating coumarin into wound dressings within an experimental model. Our synthesized target compound 3-(3-(4-hydroxy-2-oxo-2 H -chromen-3-yl)-5-(pyridin-3-yl)-1 H -pyrazol-1-yl) indolin-2-one ( CPPI ) demonstrated notable antimicrobial activity against the pathogenic Staphylococcus aureus MRSA, Bacillus cereus , and Pseudomonas aeruginosa . Moreover, both in vitro and in vivo experiments showed that CPPI significantly enhanced the migration of skin fibroblast cells and promoted the wound healing process. Furthermore, it facilitated complete re-epithelialization of the wounds. Histological analysis revealed the formation of well-structured granulation tissue and a reduction in indicators of wound infection, evidenced by a minimal presence of inflammatory cells in comparison to untreated wounds. Additionally, in silico molecular docking studies of CPPI indicated significant binding affinity within COX-2 active site along with a stable complex during molecular dynamics simulations. Collectively, the findings of this study suggest that CPPI can provide a protective effect against infections in cutaneous wounds, attributable to its antimicrobial properties.
- Open Access
- 5 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (39) , 32821-32832
Design, synthesis and molecular modeling of new coumarin–thiazole derivatives as dual EGFR/HDAC1 inhibitors: in vitro and in vivo anticancer assays
The growing evidence ascertaining the overexpression of EGFR and HDAC1 in breast and colorectal cancers prompted us to design and synthesize some new coumarin–thiazole derivatives with dual EGFR/HDAC1 inhibitory activity, considering the nature of EGFR and HDAC inhibitory models. The new derivatives were evaluated for their in vitro cytotoxicity against HCT-116 and MCF-7 cancer cells along with BJ-1 normal cells. Compound 3-(-1-((-5-(-(4-bromophenyl)diazenyl)-4-methylthiazol-2(3H)-ylidene)hydrazono)ethyl)-4-hydroxy-2H-chromen-2-one (3m) showed promising selectivity indices for both cell lines, preferential inhibition of EGFR/HDAC1/ERK, induction of cell cycle arrest and apoptosis, and significant in vivo antitumor activity against Ehrlich ascites and solid carcinoma models. Docking study showed that the selected compound attained promising results within the active sites of EGFR and HDAC1.
- 5 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (39) , 32821-32832
Open AccessDesign, synthesis and molecular modeling of new coumarin–thiazole derivatives as dual EGFR/HDAC1 inhibitors: in vitro and in vivo anticancer assays
The growing evidence ascertaining the overexpression of EGFR and HDAC1 in breast and colorectal cancers prompted us to design and synthesize some new coumarin–thiazole derivatives with dual EGFR/HDAC1 inhibitory activity, considering the nature of EGFR and HDAC inhibitory models. The new derivatives were evaluated for their in vitro cytotoxicity against HCT-116 and MCF-7 cancer cells along with BJ-1 normal cells. Compound 3-(-1-((-5-(-(4-bromophenyl)diazenyl)-4-methylthiazol-2(3H)-ylidene)hydrazono)ethyl)-4-hydroxy-2H-chromen-2-one (3m) showed promising selectivity indices for both cell lines, preferential inhibition of EGFR/HDAC1/ERK, induction of cell cycle arrest and apoptosis, and significant in vivo antitumor activity against Ehrlich ascites and solid carcinoma models. Docking study showed that the selected compound attained promising results within the active sites of EGFR and HDAC1.
- 11 March 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 159, 108338
In vitro and in vivo antidiabetic evaluation of new Coumarin and Chromone derivatives: Design, synthesis and molecular modeling
- 11 March 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 159, 108338
In vitro and in vivo antidiabetic evaluation of new Coumarin and Chromone derivatives: Design, synthesis and molecular modeling
- 17 November 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1323
Design, synthesis and molecular docking studies of tailored coumarin and chromone derivatives for use as anti-Alzheimer agents
- 17 November 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1323
Design, synthesis and molecular docking studies of tailored coumarin and chromone derivatives for use as anti-Alzheimer agents
- Open Access
- 12 July 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (31) , 22434-22448
Naturally based pyrazoline derivatives as aminopeptidase N, VEGFR2 and MMP9 inhibitors: design, synthesis and molecular modeling
Aminopeptidase N (APN) is regarded as an attractive target for cancer treatment due to its overexpression in various types of malignancies and its close association with cancer angiogenesis, metastasis and invasion. Herein the authors describe the design, synthesis and biological evaluation of some naturally based pyrazoline derivatives. Among these compounds, the diphenylpyrazole carbothioamide 8 showed significant activity and selectivity index (SI = 4.7) on breast (MCF-7) human cancer cell line and was capable of inhibiting APN with pIC50 value of 4.8, comparable to the reference standard. Further evaluation of derivative 8 against VEGFR2 and MMP9 as biomarkers for angiogenesis and invasion showed that the selected compound had an inhibitory activity on both proteins with pIC50 values of 6.7 and 6.4, respectively. Additionally, the migration ability of cells following treatment with the diphenylpyrazole derivative decreased to record a percentage wound closure of 57.77 for compound 8 versus 97.03 for the control. The promising derivative arrested cell growth at the G1 phase inducing early and late apoptosis. Finally, docking and ADMET in silico studies were performed.
- 12 July 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (31) , 22434-22448
Open AccessNaturally based pyrazoline derivatives as aminopeptidase N, VEGFR2 and MMP9 inhibitors: design, synthesis and molecular modeling
Aminopeptidase N (APN) is regarded as an attractive target for cancer treatment due to its overexpression in various types of malignancies and its close association with cancer angiogenesis, metastasis and invasion. Herein the authors describe the design, synthesis and biological evaluation of some naturally based pyrazoline derivatives. Among these compounds, the diphenylpyrazole carbothioamide 8 showed significant activity and selectivity index (SI = 4.7) on breast (MCF-7) human cancer cell line and was capable of inhibiting APN with pIC50 value of 4.8, comparable to the reference standard. Further evaluation of derivative 8 against VEGFR2 and MMP9 as biomarkers for angiogenesis and invasion showed that the selected compound had an inhibitory activity on both proteins with pIC50 values of 6.7 and 6.4, respectively. Additionally, the migration ability of cells following treatment with the diphenylpyrazole derivative decreased to record a percentage wound closure of 57.77 for compound 8 versus 97.03 for the control. The promising derivative arrested cell growth at the G1 phase inducing early and late apoptosis. Finally, docking and ADMET in silico studies were performed.
- 25 June 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1318
Design, synthesis and molecular modeling of pyrazoline based coumarin derivatives as tubulin polymerization inhibitors
- 25 June 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1318
Design, synthesis and molecular modeling of pyrazoline based coumarin derivatives as tubulin polymerization inhibitors
- Open Access
- 4 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (42) , 29070-29085
EGFR and PI3K/m-TOR inhibitors: design, microwave assisted synthesis and anticancer activity of thiazole–coumarin hybrids
A series of thiazoline and thiazolidinone-based 4-hydroxycoumarin derivatives were synthesized using both conventional synthesis procedures and microwave-assisted techniques. The new compounds were evaluated for their cytotoxic effect against three human cancer cell lines; MCF-7, HCT-116 and HepG2 and one normal human cell line (BJ-1). The promising anti-proliferative compounds 2a, 2b, 6a and 6b were assessed for inhibiting EGFR and PI3K/mTOR. Compound 6a showed the highest inhibition activity towards the signaling pathway. The apoptotic effect and cell cycle arrest potential of derivative 6a were examined. Moreover, the molecular docking, physicochemical properties and pharmacokinetic parameters of the promising compound were investigated, as well.
- 4 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (42) , 29070-29085
Open AccessEGFR and PI3K/m-TOR inhibitors: design, microwave assisted synthesis and anticancer activity of thiazole–coumarin hybrids
A series of thiazoline and thiazolidinone-based 4-hydroxycoumarin derivatives were synthesized using both conventional synthesis procedures and microwave-assisted techniques. The new compounds were evaluated for their cytotoxic effect against three human cancer cell lines; MCF-7, HCT-116 and HepG2 and one normal human cell line (BJ-1). The promising anti-proliferative compounds 2a, 2b, 6a and 6b were assessed for inhibiting EGFR and PI3K/mTOR. Compound 6a showed the highest inhibition activity towards the signaling pathway. The apoptotic effect and cell cycle arrest potential of derivative 6a were examined. Moreover, the molecular docking, physicochemical properties and pharmacokinetic parameters of the promising compound were investigated, as well.
- 14 March 2022
- Published by Wiley in Archiv der Pharmazie
- Vol. 355 (6) , e2100327
Antitumor and multikinase inhibition activities of some synthesized coumarin and benzofuran derivatives
Two new series of coumarin and benzofuran derivatives were designed, synthesized, and assessed for their in vitro and in vivo antitumor activities against breast cancer. Compounds 8, 9, 14, 15, and 17 exhibited the best antiproliferative activities (IC50: 0.07−2.94 μM) against the MCF‐7 cell line, compared with lapatinib (IC50: 4.69 μM). Compound 14, with the most potent cytotoxic activity against MCF‐7 cells, was capable of enhancing preG1 apoptosis and triggering cell cycle arrest at the G2/M phase. The kinase inhibitory activity of compound 14 against a panel of 22 kinases was examined to reveal multikinase inhibition within −39% to −97%. Furthermore, compound 14 exhibited potent in vivo Ehrlich (mammary adenocarcinoma) tumor regression, positive caspase‐3, and negative EGFR immunoreaction, and was capable of elevating the catalase level. The physicochemical properties and pharmacokinetic parameters of compound 14 were investigated in silico for its druglikeness.
- 14 March 2022
- Published by Wiley in Archiv der Pharmazie
- Vol. 355 (6) , e2100327
Antitumor and multikinase inhibition activities of some synthesized coumarin and benzofuran derivatives
Two new series of coumarin and benzofuran derivatives were designed, synthesized, and assessed for their in vitro and in vivo antitumor activities against breast cancer. Compounds 8, 9, 14, 15, and 17 exhibited the best antiproliferative activities (IC50: 0.07−2.94 μM) against the MCF‐7 cell line, compared with lapatinib (IC50: 4.69 μM). Compound 14, with the most potent cytotoxic activity against MCF‐7 cells, was capable of enhancing preG1 apoptosis and triggering cell cycle arrest at the G2/M phase. The kinase inhibitory activity of compound 14 against a panel of 22 kinases was examined to reveal multikinase inhibition within −39% to −97%. Furthermore, compound 14 exhibited potent in vivo Ehrlich (mammary adenocarcinoma) tumor regression, positive caspase‐3, and negative EGFR immunoreaction, and was capable of elevating the catalase level. The physicochemical properties and pharmacokinetic parameters of compound 14 were investigated in silico for its druglikeness.
- 23 December 2021
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 99 (3) , 470-482
Design, synthesis, and molecular modeling of quinoline‐based derivatives as anti‐breast cancer agents targeting EGFR/AKT signaling pathway
Two series of quinoline–thiazole and quinoline–thiazolidinone hybrids were designed, synthesized, and evaluated for their in vitro antitumor activity on MCF‐7 breast cancer cell line. In comparison with lapatinib (IC50 = 4.69 µM), compounds 4b and 6b exhibited the best antiproliferative activity with IC50 values of 33.19 and 5.35 µM, respectively. Although compound 6b showed higher cytotoxicity, compound 4b exhibited better inhibitory activity toward the epidermal growth factor receptor (EGFR) pathway than compound 6b as represented by the significant reduction in the EGFR kinase activity and the levels of phosho‐EGFR and phosho‐AKT when compared to lapatinib as a reference standard. Moreover, compound 4b was capable of down‐regulating the anti‐apoptotic genes Bcl‐2 and survivin and up‐regulating the level of the pro‐apoptotic gene BAX. Molecular modeling study was carried out to predict the binding interactions of both compounds into the target kinase. Finally, the physicochemical properties were investigated in silico as well.
- 23 December 2021
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 99 (3) , 470-482
Design, synthesis, and molecular modeling of quinoline‐based derivatives as anti‐breast cancer agents targeting EGFR/AKT signaling pathway
Two series of quinoline–thiazole and quinoline–thiazolidinone hybrids were designed, synthesized, and evaluated for their in vitro antitumor activity on MCF‐7 breast cancer cell line. In comparison with lapatinib (IC50 = 4.69 µM), compounds 4b and 6b exhibited the best antiproliferative activity with IC50 values of 33.19 and 5.35 µM, respectively. Although compound 6b showed higher cytotoxicity, compound 4b exhibited better inhibitory activity toward the epidermal growth factor receptor (EGFR) pathway than compound 6b as represented by the significant reduction in the EGFR kinase activity and the levels of phosho‐EGFR and phosho‐AKT when compared to lapatinib as a reference standard. Moreover, compound 4b was capable of down‐regulating the anti‐apoptotic genes Bcl‐2 and survivin and up‐regulating the level of the pro‐apoptotic gene BAX. Molecular modeling study was carried out to predict the binding interactions of both compounds into the target kinase. Finally, the physicochemical properties were investigated in silico as well.